Pfizer (PFE) Could Be 10% Undervalued Following Raised Revenue Guidance

Simply Wall St.08-13 17:26

Pfizer (PFE) is back in focus after its second quarter results came in ahead of internal expectations, prompting the company to lift full year revenue guidance and spotlight progress in key non COVID ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2659130102?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/162270-main-header/1756254067137","is_english":true,"pubTime":"2026-08-13 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659130102","market":"sg","top_or_hot":-1,"title":"Pfizer (PFE) Could Be 10% Undervalued Following Raised Revenue Guidance","media":"Simply Wall St.","content":"<div>\n<p>Pfizer (PFE) is back in focus after its second quarter results came in ahead of internal expectations, prompting the company to lift full year revenue guidance and spotlight progress in key non COVID ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/pfizer-pfe-could-be-10-undervalued-following-raised-revenue\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer (PFE) Could Be 10% Undervalued Following Raised Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer (PFE) Could Be 10% Undervalued Following Raised Revenue Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-13 17:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/pfizer-pfe-could-be-10-undervalued-following-raised-revenue><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer (PFE) is back in focus after its second quarter results came in ahead of internal expectations, prompting the company to lift full year revenue guidance and spotlight progress in key non COVID ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/pfizer-pfe-could-be-10-undervalued-following-raised-revenue\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0225284248.USD","symbol_name":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/pfizer-pfe-could-be-10-undervalued-following-raised-revenue","article_id":"2659130102","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/162270-main-header/1756254067137"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/pfizer-pfe-could-be-10-undervalued-following-raised-revenue","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2659130102","pubTimestamp":1786613176,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Pfizer (PFE) is back in focus after its second quarter results came in ahead of internal expectations, prompting the company to lift full year revenue guidance and spotlight progress in key non COVID therapies.\nSee our latest analysis for Pfizer.\nPfizer's recent earnings beat, higher full year revenue guidance and progress in drugs like Eliquis and LITFULO have coincided with a 7.5% 30 day share price return and an 11.9% 1 year total shareholder return, although longer term total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4007":"制药","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4599":"减肥药","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999002232.USD":"Allianz Global High Payout USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0234572021.USD":"高盛美国核心股票组合Acc","PFE":"辉瑞","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4592":"伊斯兰概念","OZEM":"Roundhill GLP-1 & Weight Loss ETF","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4550":"红杉资本持仓","LU2596442595.SGD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (SGDHDG) INC","BK4568":"美国抗疫概念","BK4588":"碎股","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999001176.USD":"United Global Healthcare Acc USD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4581":"高盛持仓","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M"},"translate_title":"上调收入指引后，辉瑞 (PFE) 可能被低估 10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1.98,"OZEM":0.6},"content_text":"Pfizer (PFE) is back in focus after its second quarter results came in ahead of internal expectations, prompting the company to lift full year revenue guidance and spotlight progress in key non COVID therapies. See our latest analysis for Pfizer. Pfizer's recent earnings beat, higher full year revenue guidance and progress in drugs like Eliquis and LITFULO have coincided with a 7.5% 30 day share price return and an 11.9% 1 year total shareholder return, although longer term total shareholder returns remain weak. If you want to see how other healthcare names are responding to similar trends in new treatments and pipelines, it could be worth scanning 43 healthcare AI stocks After a 7.5% 30 day jump, Pfizer still trades below both analyst targets and some intrinsic value estimates. Is that discount a sign the market is too cautious, or a fair reflection of patent risks and recent impairments? AdvertisementMost Popular Narrative: 9.9% Undervalued The most followed narrative on Pfizer pegs fair value at about $29.19 a share, slightly above the last close at $26.31, and builds that gap around pipeline execution and long term margin assumptions.  Robust expansion of Pfizer's late-stage pipeline, especially in oncology and rare diseases, with multiple high-potential launches and label expansions (e.g., Elrexfio in multiple myeloma, SV in non-small cell lung cancer, advanced ADC portfolio, and pipeline vaccines), stands to drive sustained long-term revenue and earnings growth by addressing rising global demand for innovative therapies as the population ages.  Read the complete narrative. Want to see what sits behind that pipeline story and fair value gap? The narrative focuses on future earnings power, margin rebuild, and a richer earnings multiple tied to those targets. Result: Fair Value of $29.19 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Pfizer's story can change quickly if patent expiries on key drugs bite harder than expected, or if tighter drug pricing rules compress margins faster than analysts model. Find out about the key risks to this Pfizer narrative. Another Look At Pfizer’s Valuation Using P/E The SWS DCF model flags Pfizer as trading about 64% below an assessed fair value of $73.57 per share, which suggests a wide upside gap. The P/E picture is very different. At 34.6x earnings versus a fair ratio of 24.4x and a US Pharmaceuticals average of 17.2x, the stock screens expensive. Which lens do you treat as more reliable for your own work? To see how this earnings based view compares with detailed ratio work, check the valuation breakdown next through See what the numbers say about this price — find out in our valuation breakdown. NYSE:PFE P/E Ratio as at Aug 2026Next Steps If the split sentiment around Pfizer has you on the fence, review the details promptly and decide where you stand based on 2 key rewards and 4 important warning signs Looking for more investment ideas beyond Pfizer? If Pfizer has sharpened your focus on quality, do not stop here. Use powerful screeners to uncover other stocks that might fit your approach.  Spot potential mispricings early and scan companies that look cheap against their fundamentals with the 49 high quality undervalued stocks. Strengthen your income plan by filtering for companies offering higher yields using the 9 dividend fortresses. Limit unpleasant surprises by concentrating on companies assessed with lower risk profiles through the 85 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2659130102","isCrawlerRequest":true}